RIYADH: Saudi-based AJA Pharma has signed a Memorandum of Understanding with UAE’s Bioventure FZ-LLC to license and supply new pharmaceutical products.
According to a bourse filing, the new additional selected pharmaceutical products in the Middle East region are set to be used in the Saudi Export stand at the upcoming Arab Health Expedition 2023.
Under the terms of the new MoU, Bioventure, a subsidiary of GlobalOne Healthcare Holding, is set to focus and develop various delivery forms including complex-to-develop formulations, diabetes, oncology, and biosimilars.
Oil prices fell to a three-week low on Tuesday as senior US officials raised hopes…
The Strait of Hormuz, through which a fifth of global oil and gas shipments usually…
A charity is supporting the rehabilitation of prisoners by offering them the opportunity to create…
In Gaza, the recovery work was carried out by the Civil Defence, which operates under…
The luteal phase occurs in the second half of a woman's cycle when they experience…
Key points14 million Afghans face acute hunger, with only one in nine receiving WFP food…